The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ketamine. It was approved in ...

The FDA said this is the first time esketamine was approved for any use. The agency approved ketamine, a related drug and an anesthetic, in 1970. Ketamine, also known as “Special K,” a party ...

For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Johnson & Johnson has announced the FDA’s approval of a first-of ...

approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major depressive disorder. The drug was first approved for in 2019 ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...